Drug Information

Drug General Information
Drug ID
D00RYU
Former ID
DIB016907
Drug Name
IPH-2102
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 2 [524057]
Company
Innate Pharma SA
Target and Pathway
Target(s) CD158b1 Target Info Antagonist [533076]
Killer cell immunoglobulin-like receptor 2DL3 Target Info Antagonist [533076]
CD158a Target Info Antagonist [533076]
KEGG Pathway Antigen processing and presentation
Natural killer cell mediated cytotoxicity
Graft-versus-host diseasehsa04612:Antigen processing and presentation
Graft-versus-host disease
NetPath Pathway IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
WikiPathways Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellWP1829:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellWP1829:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 524057ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
Ref 533076Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.